Sandoz

News

First Tysabri biosimilar cleared by FDA for MS

Sandoz and Polpharma Biologics have become the first companies to get FDA approval for a biosimilar of Biogen's blockbuster multiple sclerosis therapy Tysabri, after overc

Market Access

SteinCares and Sandoz: Bringing high-quality healthcare prod...

Recently, pharmaphorum spoke with Sebastian Katz, chief strategy officer of specialty healthcare company Stein Holding Group (SteinCares), to discuss the announcement of its licensing agree

News

So it begins: Next Humira biosimilars launch in US

This week has seen the launch of new and lower-priced biosimilars to AbbVie’s Humira (adalimumab), many months after Amgen’s Amjevita (adalimumab-atto) was released in the

News

Biosimilar uptake remains poor, but Sandoz has a plan

Sandoz is a major player in biosimilar medicines, so it’s no surprise that it is concerned about how slowly these drugs are making inroads against their brand-name equival

News

Standalone Sandoz eyes $3bn in new product sales by 2028

Novartis’ generics unit Sandoz will tell investors today that it can add $3 billion in annual sales from the launch of new products, after it spins out of its parent compa

News

Relief for Amgen as it wins Otezla patent appeal

Amgen has won a crunch appeals court ruling that delays generic competition to its big-selling psoriasis drug Otezla in the US until 2028, although it missed out on gettin

First Tysabri biosimilar cleared by FDA for MS

SteinCares and Sandoz: Bringing high-quality healthcare prod...

So it begins: Next Humira biosimilars launch in US

Biosimilar uptake remains poor, but Sandoz has a plan

Standalone Sandoz eyes $3bn in new product sales by 2028

Relief for Amgen as it wins Otezla patent appeal

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Sandoz

Editor's Picks